{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:08:25Z","timestamp":1781276905406,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/1-107-03\/503-11-001"],"award-info":[{"award-number":["503\/1-107-03\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The glucagon stimulation test (GST) is widely used to assess growth hormone (GH) and cortisol secretion, nevertheless the precise mechanisms underpinning these hormonal responses remain unclear. We have endeavoured to explore the relationship between glucose and insulin fluctuations during GST and their impact on GH and cortisol secretion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects and methods<\/jats:title><jats:p>We retrospectively studied 139 subjects (mean age 35.5 \u00b1 15.1 years, BMI 26.6 \u00b1 6.61 kg\/m\u00b2), including 62 individuals with a history of pituitary disease (27 with an intact adrenal axis) and 77 healthy controls. Standard dose intramuscular GST was performed in all subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Once BMI and age were excluded from multivariate model, the nadir of glucose concentration during GST was the sole variable associated with maximal GH secretion (\u0394GH, p&amp;lt;0.0003), while neither glucose\/insulin peak, nor \u0394glucose\/\u0394insulin concentrations contributed to \u0394GH. 100% pass rate for GH secretion above 3 ng\/ml or 1.07 ng\/ml cut-offs was observed for glucose concentrations at, or below 60 mg\/dl (3.33 mmol\/l) (for Controls), or 62 mg\/dl (3.44 mmol\/l) (for Controls and patients with an intact adrenocortical axis). Such low glucose concentrations were obtained, however, only in about 30% of studied individuals. Conversely, cortisol secretion did not correlate with glucose or insulin fluctuations, suggesting alternative regulatory mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study reveals that glucose nadir below 3.33 mmol\/l is the only biochemical biovariable linked with optimal GH secretion during GST, whereas mechanisms responsible for cortisol secretion remain unclear. We emphasize the importance of glucose monitoring during GST to validate GH stimulation and support clinical decisions in GH deficiency management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1448467","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:08:39Z","timestamp":1724839719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Determination of glucose cut-off points for optimal performance of glucagon stimulation test"],"prefix":"10.3389","volume":"15","author":[{"given":"Joanna","family":"Kawalec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Horzelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Karbownik-Lewi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Lewi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof C.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0982","article-title":"Clinical Review: The diagnosis and management of central hypoadrenalism","volume":"95","author":"Grossman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cen.15074","article-title":"Redefining ITT cortisol thresholds on Abbott platforms to prevent misdiagnosis of adrenal insufficiency","volume":"101","author":"Lazarus","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01169.x","article-title":"An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease","volume":"54","author":"Leong","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/eje.0.1430099","article-title":"Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans","volume":"143","author":"Arvat","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad019","article-title":"Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in heathy subjects","volume":"188","author":"Varaldo","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1574886316666210727152000","article-title":"Safety assessment and potential risks of the glucagon stimulation test in the diagnosis of secondary adrenal insufficiency","volume":"17","author":"Ach","year":"2022","journal-title":"Curr Drug Saf;"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2014.11.002","article-title":"Potential risks of glucagon stimulation test in elderly people","volume":"25","author":"Tavares","year":"2015","journal-title":"Growth Horm IGF Res"},{"key":"B8","article-title":"Diagnostic procedures in hypopituitary dwarfism. I. Evaluation of growth hormone deficiency: plasma growth hormone response to insulin-induced hypoglycemia, effect of HGH on nitrogen retention, insulin-tolerance-test and growth velocity","volume":"25","author":"Joss","year":"1970","journal-title":"Helv Paediatr Acta"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-40-3-442","article-title":"Effects of glucocorticoids on pituitary hormonal responses to hypoglycemia. Inhibition of prolactin release","volume":"40","author":"Copinschi","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ghir.2008.06.002","article-title":"Relationship between GH response and glycemic fluctuations in the glucagon stimulation test","volume":"19","author":"Giuffrida","year":"2009","journal-title":"Growth Horm IGF Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000200","article-title":"Is biochemical hypoglycemia necessary during an insulin tolerance test","volume":"64","author":"Simsek","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.111\/cen.12373","article-title":"How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation","volume":"81","author":"Yo","year":"2014","journal-title":"Clin Endocrinol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-007-0031-0","article-title":"Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood","volume":"10","author":"Corneli","year":"2007","journal-title":"Pituitary"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0666-1","article-title":"Can a glucagon stimulation test characterized by lower GH cut-off value be used for the diagnosis of growth hormone deficiency in adults","volume":"18","author":"Diri","year":"2015","journal-title":"Pituitary"},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ghir.2015.12.005","article-title":"Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease","volume":"26","author":"Wilson","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2830","article-title":"Overweight\/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid diagnosis of growth hormone deficiency","volume":"99","author":"Dichtel","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40618-024-02322-5","article-title":"Once upon a time: the glucagon stimulation test in diagnosing adults GH deficiency","volume":"47","author":"Cuboni","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.2.m124","article-title":"Aging-related growth hormone (GH) decrease is a selective hypothalamic GH-releasing hormone pulse amplitude mediated phenomenon","volume":"56","author":"Russell-Aulet","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00610.x","article-title":"Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST)","volume":"49","author":"Orme","year":"1998","journal-title":"Clin Endocrinol Oxf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0783-7","article-title":"Copeptin under glucagon stimulation","volume":"52","author":"Lewandowski","year":"2016","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(86)90160-5","article-title":"Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men","volume":"35","author":"Coiro","year":"1986","journal-title":"Metabolism"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb01151.x","article-title":"Effect of obesity and weight loss on the arginine vasopressin response to insulin-induced hypoglycaemia","volume":"27","author":"Coiro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/BF03350005","article-title":"The infusion of somatostatin reduces the arginine-vasopressin response to insulin-induced hypoglycemia in man","volume":"12","author":"Chiodera","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244458","article-title":"Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man","volume":"83","author":"Chiodera","year":"1991","journal-title":"J Neural Transm Gen Sect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000126185","article-title":"Hypoglycemia-induced arginine vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood-brain barrier","volume":"55","author":"Chiodera","year":"1992","journal-title":"Neuroendocrinology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800560315","article-title":"The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects","volume":"56","author":"Plumpton","year":"1969","journal-title":"Br J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0712-7","article-title":"Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study","volume":"19","author":"Hamrahian","year":"2016","journal-title":"Pituitary"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2295","article-title":"Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease","volume":"99","author":"Roussel","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2046","article-title":"Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay","volume":"92","author":"Katan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2024.171185","article-title":"The influence of insulin-induced hypoglycemia on copeptin concentrations","volume":"176","author":"Trimpou","year":"2024","journal-title":"Peptides"},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/EJE-22-0033","article-title":"Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study","volume":"187","author":"Atila","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01240-0","article-title":"The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults: Data from: Glucacop, Macicop, and CARGO study","volume":"25","author":"Atila","year":"2022","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0042","article-title":"Copeptin levels increase in response to both insulin-induced hypoglycemia and arginine but not to clonidine: data from GH-stimulation tests","volume":"12","author":"Stankovic","year":"2023","journal-title":"Endocr Connect"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112857","article-title":"Limited role of endogenous vasopressin\/copeptin in stimulation of ACTH-cortisol secretion during glucagon stimulation test in humans","volume":"10","author":"Malicka","year":"2022","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1430601","article-title":"Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans","volume":"143","author":"Arvat","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"B36","first-page":"397","article-title":"Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications","volume":"22","author":"Scheen","year":"1996","journal-title":"Diabetes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1448467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:08:44Z","timestamp":1724839724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1448467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":36,"alternative-id":["10.3389\/fendo.2024.1448467"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1448467","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"article-number":"1448467"}}